This grant effort has recently discovered that the Peyer's patches, which are the major mucosal inductive sites in the gastrointestinal (GI) immune system, are not strictly required for mucosal IgA antibody (Ab) responses after oral immunization. Mice treated in utero with lymphotoxin-beta receptor (LTbR)-Ig do not develop Peyer's patches ; however, these mice exhibit mesenteric lymph nodes which drain the small intestine. In this regard, oral immunization of LTbR-Ig treated mice with protein and cholera toxin (CT) as mucosal adjuvant resulted in significant IgA Ab responses in the GI tract. Preliminary studies suggested that the mesenteric lymph nodes served as a compensatory site for these IgA Ab responses. In addition, we discovered that Peyer's patches are a strict requirement for oral tolerance to proteins such as ovalbumin (OVA), but not to haptens such as trinitrophenyl sulfonic acid (TNBS). Clear proof that Peyer's patches are required for oral tolerance to proteins was provided by an experiment where TNBS conjugated to OVA (TNP-OVA) failed to induce oral tolerance to either TNBS or to OVA in LTbR-Ig treated mice. These experiments reveal fundamental differences in a requirement for Peyer's patches in mucosal immunity versus oral tolerance and provide us with a platform to simultaneously study these responses in the GI tract. In this renewal application, the first specific aim will characterize the mesenteric lymph nodes of LTbR-Ig treated, Peyer's patch null mice as alternate IgA inductive sites. We will characterize B cells and plasma cells with emphasis on u > a switches, and for TGF-b 1 expression. The second specific aim will focus on CD4+ T helper (Th) cells and especially Th1-type cells for mucosal IgA Ab responses in the GI tract. Major emphasis will be placed on recombinant Salmonella expressing OVA for initiation of mucosal immunity in Peyer's patch-null mice. The third specific aim will assess the role of antigen-presenting cells (APCs) in Peyer's patches for IgA immunity versus oral tolerance induction. Emphasis will be placed on dendritic cells (DCs), in a natural environment or after activation with Flt3 ligand. The fourth specific aim will employ OVA peptide-specific tetramers to track CD4+ T cells from Peyer's patches to the periphery under conditions for mucosal IgA or oral tolerance responses. The last specific aim will bridge mucosal IgA Ab responses with oral tolerance induction. In this regard, we will study the mechanism of the switch from oral tolerance to IgA immunity which occurs when CT is used as an oral adjuvant. The seminal findings which have emanated from this grant effort since 1982 will again remain focused on the cellular and molecular events required for induction of mucosal immunity or oral tolerance in the GI tract.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI018958-21
Application #
6631650
Study Section
Special Emphasis Panel (ZRG1-SSS-F (01))
Program Officer
Rothermel, Annette L
Project Start
1982-09-30
Project End
2006-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
21
Fiscal Year
2003
Total Cost
$287,000
Indirect Cost
Name
University of Alabama Birmingham
Department
Dentistry
Type
Schools of Dentistry
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Boyaka, Prosper N (2017) Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. J Immunol 199:9-16
Martin, Tara L; Jee, Junbae; Kim, Eunsoo et al. (2017) Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. Vaccine 35:2511-2519
Fukuiwa, Tatsuya; Sekine, Shinichi; Kobayashi, Ryoki et al. (2008) A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26:4849-59
Suzuki, Hideaki; Sekine, Shinichi; Kataoka, Kosuke et al. (2008) Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 135:917-25
Sekine, Shinichi; Kataoka, Kosuke; Fukuyama, Yoshiko et al. (2008) A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. J Immunol 180:8126-34
Rynda, Agnieszka; Maddaloni, Massimo; Mierzejewska, Dagmara et al. (2008) Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. J Immunol 180:5187-200
Kataoka, Kosuke; Fujihashi, Keiko; Sekine, Shinichi et al. (2007) Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses. J Immunol 178:6058-65
Duverger, Alexandra; Jackson, Raymond J; van Ginkel, Frederick W et al. (2006) Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol 176:1776-83
Hagiwara, Yukari; Kawamura, Yuki I; Kataoka, Kosuke et al. (2006) A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol 177:3045-54
Maddaloni, Massimo; Staats, Herman F; Mierzejewska, Dagmara et al. (2006) Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol 177:5524-32

Showing the most recent 10 out of 185 publications